H
Hantavirus 2026
Treatment

No cure — but timing changes everything

There is no antiviral approved for Hantavirus Pulmonary Syndrome and no licensed vaccine in the United States. Survival depends almost entirely on how early a patient reaches an intensive care unit equipped to manage rapid respiratory failure.

The clinical course

  1. 01

    Recognition

    Clinicians who suspect HPS in a patient with fever, myalgia, and recent rodent exposure should isolate the patient, draw labs (CBC with smear, metabolic panel, lactate), and arrange transfer to a facility with ICU capability immediately — before respiratory symptoms appear.

  2. 02

    Supportive care

    Once cardiopulmonary symptoms develop, deterioration can be rapid. Care centers on careful fluid management, supplemental oxygen, and mechanical ventilation as needed. Over-resuscitation worsens pulmonary edema.

  3. 03

    Advanced support

    ECMO (extracorporeal membrane oxygenation) has improved survival in the sickest patients during the cardiopulmonary phase. Early referral to an ECMO-capable center is associated with better outcomes.

  4. 04

    Recovery

    Patients who survive the cardiopulmonary phase typically recover lung function over weeks to months, though fatigue and reduced exercise tolerance can persist.

What does not work

Ribavirin showed benefit in some Old World hantavirus infections (HFRS) but has not been shown to improve outcomes in New World HPS once the cardiopulmonary phase begins. Corticosteroids have not demonstrated benefit. Antibiotics treat secondary infection only. There is no role for empiric outpatient management once HPS is suspected.

Vaccine status

No Hantavirus vaccine is licensed in the United States or Europe. Inactivated vaccines against Hantaan and Seoul viruses are used in parts of Asia. Several candidates for New World hantaviruses are in early-stage research; none are clinically available.

For clinicians

Suspect HPS? Transfer before respiratory failure, not after.

Outcomes correlate strongly with proximity to ECMO capability at the moment of decompensation. Coordinate transfer in the prodromal phase whenever epidemiology supports the diagnosis.